CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.
Müller F, Hagen M, Wirsching A, Kharboutli S, Aigner M, Völkl S, Kretschmann S, Tascilar K, Taubmann J, Bucci L, Raimondo MG, Bergmann C, Rothe T, Corte G, Tur C, Muñoz L, Böltz S, Schuster L, Hartmann F, Garantziotis P, Spörl S, Vasova I, Gerbitz A, Spriewald B, Kiener H, Giannarelli D, Locatelli F, D'Agostino MA, Hanssens L, Miltenyi S, Bozec A, Grieshaber-Bouyer R, Mackensen A, Schett G.
Müller F, et al. Among authors: tur c.
Nat Med. 2026 Jan 7. doi: 10.1038/s41591-025-04185-6. Online ahead of print.
Nat Med. 2026.
PMID: 41501497